Moderna Inc. ($MRNA) Stock Forecast: Down 5.2% Today

What is Moderna Inc.?

Moderna Inc. (NASDAQ: MRNA) is a Massachusetts-based biotech company known for its innovative approach to developing vaccines, including its widely discussed COVID-19 vaccine.

Why is Moderna Inc. going down?

MRNA stock is down 5.2% on Nov 20, 2025 19:05

• Moderna stock saw a decrease in value after two notable revelations concerning its finances and business strategy.
• Market sentiment towards the company may have turned pessimistic, reflecting potential apprehensions regarding its future financial trajectory and strategic decisions.
• Investors could be adopting a watchful stance on Moderna until further details emerge on the implications of these announcements for the company's expansion opportunities.

MRNA Price Chart

MRNA Technical Analysis

MRNA News

What's Going On With Moderna Stock? - Moderna ( NASDAQ:MRNA )

Shares of Moderna, Inc. ( NASDAQ:MRNA ) are falling Thursday. The Massachusetts-based biotech company made two significant announcements regarding its finances and business strategy. MRNA is lagging behind market performance. See if it is worth your attention here.

https://www.benzinga.com/trading-ideas/movers/25/11/48983817/whats-going-on-with-moderna-stock

Trending Today

Moderna Inc. Price History

03.10.2025 - MRNA Stock was down 5.8%

• Moderna (MRNA) stock saw a downward trend today, which could be linked to profit-taking following recent gains.
• A decline in short interest suggests a potential loss of market backing, potentially contributing to the stock's decline.
• Worries about the upcoming Q3 earnings drop may have impacted investor confidence and fueled the bearish movement.
• Despite recent fluctuations, Moderna's long-term outlook and innovative mRNA technology show promise, positioning it as a stock worth monitoring for future developments.

04.10.2025 - MRNA Stock was down 5.1%

• MRNA stock faced a bearish trajectory attributed to various factors:
• Declining demand for the COVID-19 vaccine affecting the company's earnings forecast.
• Recent setbacks in clinical trials overshadowing positive pipeline updates and causing unease among investors.
• Despite prior stock price surges, the trend in earnings estimate revisions may not support further upward momentum.
• Reduced short interest suggesting potential waning market backing, contributing to the stock's downward pressure.

04.10.2025 - MRNA Stock was down 5.1%

• MRNA stock experienced a bearish movement likely due to:
• Earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand impacts its outlook.
• Recent clinical setbacks overshadowing positive pipeline news, causing investor concern.
• Market sentiment shifting as short interest in MRNA shares decreases, indicating potential loss of market support.
• The combination of these factors contributed to the strong bearish movement in MRNA stock as investors reevaluate the company's growth prospects amidst evolving market conditions.

09.09.2025 - MRNA Stock was down 5.6%

• Despite recent developments, Moderna's stock experienced a bearish movement today.
• The discrepancy between noteworthy developments and the stock's movement could be attributed to profit-taking by investors.
• Market sentiment or broader economic factors may have affected Moderna's stock performance, overshadowing recent positive news.
• Investors should consider both company-specific updates and market conditions when trading Moderna's stock.

31.09.2025 - MRNA Stock was up 12.4%

• Moderna (MRNA) saw a robust upward movement, with a notable 13.9% increase in its stock price.
• A 12.38% decline in short interest hints at growing market support and favorable sentiment towards the company.
• Despite predictions of a Q3 earnings decrease, Moderna's stock outperformed the broader market, indicating investor confidence in its future growth.
• The recent trend in earnings estimate revisions may not sustain the stock's current upward trajectory, signaling potential volatility ahead.

30.09.2025 - MRNA Stock was up 8.0%

• Despite expectations of a decline in Q3 earnings, Moderna (MRNA) surprised the market with a strong bullish movement, outperforming the broader market.
• The bullish movement could be attributed to investor optimism surrounding the company's potential for future vaccine developments and revenue growth.
• The market may be reacting positively to Moderna's resilience and ability to navigate challenges, showcasing confidence in its long-term prospects.
• This unexpected bullish movement showcases how investor sentiment and market performance can sometimes diverge from analysts' expectations.

30.09.2025 - MRNA Stock was up 17.5%

• The decrease in short interest suggests a rising positive sentiment towards Moderna's stock.
• Despite anticipated Q3 earnings decline, Moderna outperformed the broader market, demonstrating resilience and investor confidence.
• The optimistic market movement may be due to excitement about the company's innovative mRNA technology and potential future developments in the healthcare sector.
• Investors appear to be placing more importance on Moderna's long-term growth potential rather than short-term earnings fluctuations, fueling the bullish trend in the stock.

11.10.2025 - MRNA Stock was up 5.0%

• The company recorded a third-quarter loss that was notably under projections, signaling a solid financial performance.
• Moderna's quarterly sales surpassed estimates, highlighting its robust revenue generation.
• The favorable outcomes in earnings and revenue suggest a promising financial trajectory for Moderna, potentially bolstering investor confidence and fueling the upward trend in its stock price.
• The revised sales forecast, coupled with the exceptional financial results, likely played a significant role in driving Moderna's stock price upward today.

28.09.2025 - MRNA Stock was down 5.1%

• Moderna's stock (MRNA) experienced a strong bearish movement today, closing at $26.85 with a -2.33% change from the previous day.
• The market reacted negatively to the news that Moderna halted its CMV vaccine program due to the vaccine falling short in preventing infection in a Phase 3 trial.
• Investors might be concerned about the company's future pipeline and potential setbacks in developing new vaccines.
• This news highlights the volatility and risks associated with biotech stocks, where clinical trial results can significantly impact stock performance.

20.10.2025 - MRNA Stock was down 5.2%

• Moderna stock saw a decrease in value after two notable revelations concerning its finances and business strategy.
• Market sentiment towards the company may have turned pessimistic, reflecting potential apprehensions regarding its future financial trajectory and strategic decisions.
• Investors could be adopting a watchful stance on Moderna until further details emerge on the implications of these announcements for the company's expansion opportunities.

15.09.2025 - MRNA Stock was up 5.3%

• Moderna's stock (MRNA) demonstrated strong bullish movement today, surpassing the market performance.
• Positive response rates for its skin cancer combo therapy and encouraging early data for its investigational cancer antigen therapy presented at the 2025 European Society for Medical Oncology Congress likely influenced the bullish trend.
• Investor optimism regarding Moderna's progress in cancer treatment is fueling the increase in stock price, with expectations of future growth in this sector.
• The company's track record of innovation and promising results in the oncology field is attracting investor attention and bolstering confidence in Moderna's long-term prospects, evident in the stock's upward trajectory.

14.09.2025 - MRNA Stock was down 5.7%

• Promising early data for Moderna's investigational cancer antigen therapy, mRNA-4359, was presented at a medical oncology congress, suggesting potential progress in cancer treatment.
• Despite advancements in cancer therapies, Moderna's stock saw a decline, possibly attributed to profit-taking following recent gains or shifts in market sentiment.
• The market's reaction to the data presentation may have been negative, with expectations for more immediate commercialization or revenue impact not being met, contributing to the stock's bearish movement.